<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">xFQ3KgpsmhGBSwRwSX7VYvC</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2004001500009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(04)08300309</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2004001500009</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estenose mitral grave como evolu&#231;&#227;o a longo prazo de miotomia/miectomia septal cir&#250;rgica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Soeiro</surname>
            <given-names>Alexandre de Matos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Juliana Ascen&#231;&#227;o de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Serrano J&#250;nior</surname>
            <given-names>Carlos Vicente</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Benvenuti</surname>
            <given-names>Luiz Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miranda</surname>
            <given-names>Reynaldo Castro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nicolau</surname>
            <given-names>Jos&#233; Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ramires</surname>
            <given-names>Jos&#233; Ant&#244;nio F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>S&#233;rgio Almeida de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <institution content-type="orgname">USP</institution>
        <institution content-type="orgdiv1">FM </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>09</month>
        <year>2004</year>
      </pub-date>
      <volume>83</volume>
      <issue>3</issue>
      <fpage>253</fpage>
      <lpage>257</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>09</month>
        <year>2004</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>Estenose mitral grave como evolu&#231;&#227;o a longo prazo de miotomia/miectomia septal cir&#250;rgica</p>
    <p>Alexandre de Matos Soeiro; Juliana Ascen&#231;&#227;o de Souza; Carlos Vicente Serrano J&#250;nior; Luiz Alberto Benvenuti; Reynaldo Castro Miranda; Jos&#233; Carlos Nicolau; Jos&#233; Ant&#244;nio F. Ramires; S&#233;rgio Almeida de Oliveira </p>
    <p> S&#227;o Paulo, SP</p>
    <p>InCor do Hospital das Cl&#237;nicas da FMUSP</p>
    <p>
      <italic>Mulher de 67 anos de idade, apresentando estenose mitral grave, n&#227;o-reum&#225;tica, ap&#243;s 18 anos da realiza&#231;&#227;o de miotomia/miectomia septal cir&#250;rgica para corre&#231;&#227;o de miocardiopatia hipertr&#243;fica septal assim&#233;trica. A paciente foi submetida a troca da valva mitral por pr&#243;tese mec&#226;nica, tornando-se caso &#250;nico, em raz&#227;o da combina&#231;&#227;o das duas s&#237;ndromes, extremamente rara e com grave progn&#243;stico.</italic>
    </p>
    <p>A miocardiopatia hipertr&#243;fica, tamb&#233;m conhecida como estenose suba&#243;rtica hipertr&#243;fica idiop&#225;tica ou miocardiopatia obstrutiva hipertr&#243;fica, &#233; uma doen&#231;a, classicamente, caracterizada por hipertrofia ventricular esquerda n&#227;o-dilatada, na aus&#234;ncia de qualquer outra causa de aumento da massa mioc&#225;rdica<sup>1-4</sup>. Sua incid&#234;ncia varia de 0,02% a 5% na popula&#231;&#227;o em geral<sup>1,5</sup> e, em cerca de metade dos casos, &#233; uma doen&#231;a gen&#233;tica, com padr&#227;o de transmiss&#227;o autoss&#244;mico dominante e express&#227;o vari&#225;vel. No restante, pode resultar de muta&#231;&#245;es novas ou de transmiss&#227;o autoss&#244;mica recessiva, com penetr&#226;ncia reduzida do gene<sup>1,4,6</sup>.</p>
    <p>O padr&#227;o de hipertrofia mioc&#225;rdica geralmente &#233; heterog&#234;neo e segmentos cont&#237;guos do ventr&#237;culo esquerdo podem apresentar grande diferen&#231;a em sua espessura. Mais freq&#252;entemente, a hipertrofia envolve o septo interventricular, cuja espessura encontra-se desproporcionalmente aumentada em rela&#231;&#227;o &#224; parede livre do ventr&#237;culo esquerdo, caracterizando a miocardiopatia hipertr&#243;fica septal assim&#233;trica<sup>2,4-6</sup>. Independentemente de seu padr&#227;o morfol&#243;gico, a miocardiopatia hipertr&#243;fica septal assim&#233;trica apresenta um arranjo bizarro e desorganizado das c&#233;lulas musculares no septo, com altera&#231;&#227;o da arquitetura miofibrilar, independentemente da presen&#231;a ou n&#227;o de gradiente de press&#227;o sist&#243;lica intraventricular, em associa&#231;&#227;o com fibrose mioc&#225;rdica vari&#225;vel e espessamento das pequenas art&#233;rias coron&#225;rias intramurais. A anormalidade fisiopatol&#243;gica presente &#233; diast&#243;lica, caracterizada pela maior rigidez do m&#250;sculo hipertrofiado, que resulta, primariamente, de uma anormalidade do manejo do c&#225;lcio intracelular, acarretando aumento das press&#245;es de enchimento diast&#243;lico<sup>4, 6</sup>.</p>
    <p>Aproximadamente 5% a 10% dos pacientes com miocardiopatia hipertr&#243;fica septal assim&#233;trica s&#227;o refrat&#225;rios ao tratamento cl&#237;nico, sendo indicadas terap&#234;uticas mais agressivas, como, por exemplo, miotomia/miectomia septal cir&#250;rgica, marcapasso de dupla c&#226;mara, alcooliza&#231;&#227;o da art&#233;ria septal, implante de desfibrilador (utilizado em casos com alto risco para morte s&#250;bita) e, at&#233; mesmo, realiza&#231;&#227;o de transplante card&#237;aco<sup>3,4</sup>.</p>
    <p>A estenose mitral, por sua vez, em geral &#233; de origem reum&#225;tica, ocorrendo principalmente em mulheres (cerca de 66% dos casos), e raramente &#233; cong&#234;nita<sup>7</sup>. A estenose mitral pura ou predominante ocorre em cerca de 40% de todos os pacientes com cardiopatia reum&#225;tica<sup>7</sup>. O quadro cl&#237;nico &#233; muito variado, apresentando significante rela&#231;&#227;o com o grau de acometimento valvar. Esse quadro pode variar desde a simples presen&#231;a de alguns sinais cl&#237;nicos sem sintomas at&#233; o caso em que o paciente apresente edema pulmonar, arritmias atriais, hemoptise e insufici&#234;ncia ventricular direita<sup>7</sup>.</p>
    <p>No entanto, at&#233; o momento, n&#227;o existem casos relatados na literatura cient&#237;fica demonstrando, do ponto de vista fisiopatol&#243;gico, rela&#231;&#227;o entre a miotomia/miectomia septal cir&#250;rgica e o aparecimento de estenose mitral a longo prazo.</p>
    <p>Neste relato &#233; apresentado o caso de mulher de 67 anos de idade, que, 18 anos ap&#243;s ter sido submetida a miotomia/miectomia septal cir&#250;rgica para corre&#231;&#227;o de miocardiopatia hipertr&#243;fica septal assim&#233;trica, apresentou quadro de estenose mitral grave e sintom&#225;tica. A paciente compareceu ao Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da FMUSP para avalia&#231;&#227;o cl&#237;nica adequada, e posteriormente, foi indicada a cirurgia.</p>
    <p>
      <bold>Relato do caso</bold>
    </p>
    <p>Mulher de 67 anos de idade, de cor parda, natural de Montes Claros (MG), procedente de Belo-Horizonte (MG), com quadro de dispn&#233;ia e piora progressiva h&#225; cerca de um ano, recentemente presente a m&#237;nimos esfor&#231;os (classe funcional III da <italic>New York Heart Association</italic>). A paciente apresentava, como antecedentes pessoais, hipertens&#227;o arterial sist&#234;mica e dislipidemia, al&#233;m de relatar ter sofrido acidente vascular cerebral isqu&#234;mico em 1995, sem seq&#252;elas.</p>
    <p>Em 1985, ap&#243;s realiza&#231;&#227;o de exames complementares, foram diagnosticadas miocardiopatia hipertr&#243;fica septal assim&#233;trica e hipertens&#227;o pulmonar. Naquela ocasi&#227;o, a paciente apresentava dispn&#233;ia progressiva e vertigens, mas negava hist&#243;ria de doen&#231;a reum&#225;tica. Foi indicada, ent&#227;o, miotomia/miectomia septal cir&#250;rgica, realizada por meio de aortotomia. O estudo anatomopatol&#243;gico dos fragmentos do ventr&#237;culo esquerdo retirados na cirurgia demonstrou presen&#231;a de hipertrofia de cardiomi&#243;citos, com &#225;reas de desarranjo e fibrose. No p&#243;s-operat&#243;rio, apresentou fibrila&#231;&#227;o atrial e bloqueio atrioventricular total, havendo necessidade de implante de marcapasso definitivo. A ecocardiografia transtor&#225;cica realizada no p&#243;s-operat&#243;rio evidenciou presen&#231;a de hipertrofia mioc&#225;rdica residual (septo interventricular com espessura de 1,8 cm), com fun&#231;&#227;o do ventr&#237;culo esquerdo preservada e aus&#234;ncia de sinais de obstru&#231;&#227;o suba&#243;rtica. Evidenciou, tamb&#233;m, a exist&#234;ncia de calcifica&#231;&#227;o do anel da valva mitral, por&#233;m sem evid&#234;ncia de insufici&#234;ncia ou estenose valvar.</p>
    <p>O controle tanto cl&#237;nico como ecocardiogr&#225;fico, durante os anos seguintes, demonstrou aumento progressivo do &#225;trio esquerdo, sem piora da hipertrofia mioc&#225;rdica, por&#233;m com evid&#234;ncia de comprometimento valvar mitral por estenose. Em 2002, a paciente passou a apresentar dispn&#233;ia aos esfor&#231;os, com piora progressiva e dispn&#233;ia parox&#237;stica noturna, negando outros sintomas cardiovasculares. Procurou assist&#234;ncia m&#233;dica nesse per&#237;odo, tendo sido realizada ecocardiografia transtor&#225;cica (<xref ref-type="fig" rid="fig1">fig. 1</xref>), que evidenciou &#225;trio esquerdo com aumento importante (5,7 cm de di&#226;metro), gradiente transvalvar mitral m&#233;dio de 18 mmHg e pico de 31 mmHg, com &#225;rea valvar diminu&#237;da (1,15 cm&#178;). Foi definido diagn&#243;stico de estenose mitral de grau moderado a grave, e verificada, tamb&#233;m, a exist&#234;ncia de hipertens&#227;o pulmonar (press&#227;o sist&#243;lica de art&#233;ria pulmonar de 64 mmHg). Al&#233;m disso, foi constatada presen&#231;a de septo interventricular relativamente hiperecog&#234;nico, morfologicamente alterado, com afilamento em suas por&#231;&#245;es basal, m&#233;dia e apical, e movimenta&#231;&#227;o assincr&#244;nica. A fun&#231;&#227;o sist&#243;lica global encontrava-se preservada, com fra&#231;&#227;o de eje&#231;&#227;o de 80%.</p>
    <fig id="fig1">
      <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf01.jpg"/></fig>
    <p>Apesar do tratamento medicamentoso com amiodarona (200 mg/dia), furosemida (40 mg/dia), fenito&#237;na (100 mg/dia), verapamil (120 mg/dia) e warfarin (5mg/dia), a paciente n&#227;o apresentou melhora cl&#237;nica. Optou-se, portanto, pela interna&#231;&#227;o, em abril de 2003, para que houvesse melhor avalia&#231;&#227;o do quadro cl&#237;nico por meio de adequada investiga&#231;&#227;o diagn&#243;stica.</p>
    <p>Ao exame f&#237;sico, a paciente apresentou-se em regular estado geral, corada, acian&#243;tica, anict&#233;rica, hidratada e eupn&#233;ica, com press&#227;o arterial de 130 mmHg x 70 mmHg. Foi constatada presen&#231;a de estase jugular a 45&#186;, estertores crepitantes em ambas as bases pulmonares, e f&#237;gado dolorosamente palp&#225;vel a 4 cm do rebordo costal na linha hemiclavicular direita. &#192; ausculta card&#237;aca, foram evidenciados freq&#252;&#234;ncia card&#237;aca de 70 bpm, ritmo regular, em dois tempos, hiperfonese na 1&#170; e na 2&#170; bulhas card&#237;acas de seus componentes mitral (M1) e pulmonar (P2), respectivamente, e sopro diast&#243;lico em foco a&#243;rtico e em foco mitral. O eletrocardiograma demonstrou ritmo de base de fibrila&#231;&#227;o atrial, com marcapasso funcionante em freq&#252;&#234;ncia card&#237;aca de 70 bpm. A radiografia de t&#243;rax nas incid&#234;ncias p&#243;stero-anterior e perfil esquerdo (<xref ref-type="fig" rid="f2">fig. 2</xref>) apresentou sinais sugestivos de estenose mitral e de hipertens&#227;o pulmonar. A ecocardiografia transesof&#225;gica (<xref ref-type="fig" rid="fig3">fig. 3</xref>) demonstrou valva mitral com estenose importante (&#225;rea de 1cm&#178;), insufici&#234;ncia mitral discreta e aus&#234;ncia de trombos intracavit&#225;rios. A cineangiocoronariografia e a ventriculografia evidenciaram presen&#231;a de coron&#225;rias normais, valva mitral calcificada e fun&#231;&#227;o do VE preservada.</p>
    <p content-type="asset">
      <fig id="f2">
        <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf02.jpg"/></fig>
    </p>
    <fig id="fig3">
      <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf03.jpg"/></fig>
    <p>Em raz&#227;o do quadro cl&#237;nico de estenose mitral grave, optou-se pelo tratamento cir&#250;rgico da valva mitral, sendo realizada a troca da valva por uma pr&#243;tese mec&#226;nica St. Jude 25 mm. A observa&#231;&#227;o do campo cir&#250;rgico demonstrou valva mitral intensamente espessada e estenosada, com extensa calcifica&#231;&#227;o de seu anel, a qual se estendia da valva ao &#225;pice do ventr&#237;culo esquerdo. Ainda no procedimento cir&#250;rgico, foi coletado fragmento da valva mitral medindo 2,3 cm x 2,0 cm x 0,8 cm, cuja an&#225;lise anatomopatol&#243;gica evidenciou espessamento de c&#250;spide e cordas tend&#237;neas, com &#225;reas focais de calcifica&#231;&#227;o da c&#250;spide e de fus&#227;o de cordas tend&#237;neas (<xref ref-type="fig" rid="fig4">fig. 4</xref>). Ao exame histol&#243;gico (<xref ref-type="fig" rid="fig5">fig. 5</xref>), foram verificadas fibrose, degenera&#231;&#227;o muc&#243;ide, calcifica&#231;&#227;o e &#225;reas focais de neovasculariza&#231;&#227;o. Foi observado, tamb&#233;m, que a calcifica&#231;&#227;o ocorria principalmente pr&#243;ximo &#224; borda de inser&#231;&#227;o da c&#250;spide (anel valvar).</p>
    <fig id="fig4">
      <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf04.jpg"/></fig>
    <fig id="fig5">
      <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf05.jpg"/></fig>
    <p>No p&#243;s-operat&#243;rio, a paciente apresentou complica&#231;&#245;es, como retardo da extuba&#231;&#227;o por congest&#227;o pulmonar e necessidade de drogas vasoativas e inotr&#243;picas (noradrenalina, dobutamina e milrinona). Evoluiu com infec&#231;&#227;o respirat&#243;ria e insufici&#234;ncia renal aguda, apresentando revers&#227;o total do quadro ap&#243;s a institui&#231;&#227;o de terap&#234;utica adequada.</p>
    <p>&#192; ecocardiografia realizada no per&#237;odo p&#243;s-operat&#243;rio, foi demonstrada presen&#231;a de pr&#243;tese mec&#226;nica em posi&#231;&#227;o mitral, normofuncionante, com &#225;rea valvar de 2,7 cm&#178;. Al&#233;m disso, p&#244;de ser observada manuten&#231;&#227;o da hipertens&#227;o pulmonar (press&#227;o sist&#243;lica de art&#233;ria pulmonar de 61 mmHg) e fun&#231;&#227;o do ventr&#237;culo esquerdo preservada.</p>
    <p>A paciente recebeu alta hospitalar ap&#243;s 46 dias de interna&#231;&#227;o, apresentando bom estado geral e significativa melhora da classe funcional (classe funcional I da <italic>New York Heart Association</italic>). Foram prescritos, por ocasi&#227;o da alta, warfarin (5mg/dia), losartan (50 mg/dia), amiodarona (200 mg/dia) e hidroclorotiazida (25 mg/dia).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A miocardiopatia hipertr&#243;fica septal assim&#233;trica apresenta-se, geralmente, com grande heterogeneidade em sua morfologia, em seus aspectos cl&#237;nicos e em sua evolu&#231;&#227;o<sup>1-4</sup>. H&#225; relatos de que em consider&#225;vel n&#250;mero de casos, a miocardiopatia hipertr&#243;fica septal assim&#233;trica est&#225; associada a altera&#231;&#245;es valvares, de tal maneira que na maioria de seus casos ocorre insufici&#234;ncia mitral, que, em geral, regride ap&#243;s a realiza&#231;&#227;o de miotomia/miectomia septal cir&#250;rgica<sup>2-5,8</sup>. Mais comumente, a insufici&#234;ncia mitral presente na miocardiopatia hipertr&#243;fica septal assim&#233;trica acompanha a obstru&#231;&#227;o ocasionada pelo movimento anterior sist&#243;lico da valva mitral<sup>2-4, 8</sup>.</p>
    <p>Um estudo de la Morena e cols.<sup>2</sup>, analisou as caracter&#237;sticas, por meio de ecocardiografia, de uma popula&#231;&#227;o de 72 pacientes com miocadiopatia hipertr&#243;fica, dos quais 31 eram portadores de miocardiopatia hipertr&#243;fica septal assim&#233;trica. Nos pacientes com miocardiopatia hipertr&#243;fica, foi encontrada insufici&#234;ncia mitral em 44 casos, com quadro leve em 25 pacientes, moderado em 15 e grave em 4, demonstrando estreita rela&#231;&#227;o entre miocardiopatia hipertr&#243;fica e esse problema valvar<sup>2</sup>. Al&#233;m disso, em 33 pacientes que possu&#237;am movimento anterior sist&#243;lico da valva mitral, a ocorr&#234;ncia de insufici&#234;ncia mitral foi de 78,7%, ao passo que nos pacientes em que n&#227;o foi relatado movimento anterior sist&#243;lico da valva esse &#237;ndice foi de 46,1%<sup>2</sup>.</p>
    <p>Atualmente, 5% a 10% dos pacientes s&#227;o refrat&#225;rios ao tratamento cl&#237;nico, sendo indicadas terap&#234;uticas mais agressivas. A miotomia/miectomia septal cir&#250;rgica continua sendo uma importante alternativa ao tratamento da miocardiopatia hipertr&#243;fica septal assim&#233;trica, sendo, ainda hoje, padr&#227;o de refer&#234;ncia nos pacientes muito sintom&#225;ticos, n&#227;o responsivos ao tratamento cl&#237;nico, ou em casos que possuam gradiente press&#243;rico basal <underline>&gt;</underline>30 mmHg<sup>3,4,8,9</sup>. Em muitos casos, a miotomia/miectomia septal cir&#250;rgica &#233; realizada em associa&#231;&#227;o &#224; reconstru&#231;&#227;o do anel mitral<sup>3,8,9</sup>. No entanto, a substitui&#231;&#227;o da valva mitral deve ser realizada em car&#225;ter de exce&#231;&#227;o nos casos de grande hipertrofia com insufici&#234;ncia mitral grave<sup>9</sup>.</p>
    <p>Fighali e cols.<sup>3</sup> analisaram 36 pacientes com miocardiopatia hipertr&#243;fica, submetidos a procedimentos cir&#250;rgicos, sendo que 6 pacientes realizaram miotomia/miectomia septal cir&#250;rgica e 9 a realizaram juntamente com reparo de valva mitral. No 1&#186; grupo, em um paciente n&#227;o foi diagnosticada insufici&#234;ncia mitral, 4 apresentavam insufici&#234;ncia mitral de grau leve e um tinha insufici&#234;ncia mitral de grau moderado; no 2&#186; grupo, 3 pacientes tinham insufici&#234;ncia mitral de grau leve, 2 de grau moderado e 4 de grau elevado. Ap&#243;s a realiza&#231;&#227;o da cirurgia, foi observada expressiva melhora da insufici&#234;ncia mitral em ambos os grupos. Tanto no 1&#186; grupo como no 2&#186;, somente um paciente continuou a apresentar insufici&#234;ncia valvar de grau leve<sup>3</sup>.</p>
    <p>A miotomia/miectomia septal cir&#250;rgica, portanto, melhora os quadros de miocardiopatia hipertr&#243;fica septal assim&#233;trica associados &#224; insufici&#234;ncia mitral. Al&#233;m disso, o aparecimento de insufici&#234;ncia mitral ap&#243;s miotomia/miectomia septal cir&#250;rgica n&#227;o &#233; freq&#252;ente.</p>
    <p>A sobrevida atual desse tipo de interven&#231;&#227;o gira em torno de 80% em 10 anos, apresentando bons resultados quanto &#224; melhora dos sintomas, tanto imediatos como tardios. No p&#243;s-operat&#243;rio imediato, cerca de 70% dos casos j&#225; apresentam melhora expressiva dos sintomas. A mortalidade hospitalar, por&#233;m, &#233; de cerca de 0% a 17,6%, dependendo principalmente da faixa et&#225;ria acometida, e a mortalidade intra-operat&#243;ria aproxima-se de 5%. As principais complica&#231;&#245;es desse procedimento relatadas at&#233; o momento s&#227;o o bloqueio atrioventricular total (incid&#234;ncia entre 5% e 7%), a comunica&#231;&#227;o interventricular, a endocardite e o tromboembolismo<sup>3,4,8,9</sup>.</p>
    <p>Casos de estenose mitral associada &#224; miocardiopatia hipertr&#243;fica ou a miotomia/miectomia septal cir&#250;rgica s&#227;o raros; quando presentes, s&#227;o observados em pacientes que j&#225; possu&#237;am antecedentes de doen&#231;a reum&#225;tica<sup>5,10</sup>. N&#227;o h&#225;, portanto, correla&#231;&#227;o entre essas duas doen&#231;as. At&#233; o momento, n&#227;o h&#225; nenhum caso relatado na literatura cient&#237;fica demonstrando, do ponto de vista fisiopatol&#243;gico, rela&#231;&#227;o entre miocardiopatia hipertr&#243;fica septal assim&#233;trica ou miotomia/miectomia septal cir&#250;rgica e surgimento de estenose mitral.</p>
    <p>Em nosso relato &#233; apresentada a evolu&#231;&#227;o de uma paciente com miocardiopatia hipertr&#243;fica septal assim&#233;trica, sem hist&#243;ria pr&#233;via de doen&#231;a reum&#225;tica, que desenvolveu estenose mitral ap&#243;s a realiza&#231;&#227;o de miotomia/miectomia septal cir&#250;rgica.</p>
    <p>&#192; an&#225;lise anatomopatol&#243;gica da valva, realizada com o fragmento de c&#250;spide retirado durante a &#250;ltima cirurgia, foram observadas caracter&#237;sticas que poderiam estar presentes tanto em processos degenerativos como em processos reum&#225;ticos, ou em poss&#237;vel extens&#227;o do processo cicatricial decorrente da ressec&#231;&#227;o da regi&#227;o basal do septo interventricular realizada na miotomia/miectomia septal cir&#250;rgica h&#225; 18 anos.</p>
    <p>No processo reum&#225;tico, em raz&#227;o de seu car&#225;ter inflamat&#243;rio, poderiam ser encontradas as caracter&#237;sticas relatadas tanto macrosc&#243;pica como microscopicamente, em especial no que diz respeito &#224; presen&#231;a de neovasculariza&#231;&#227;o<sup>6, 7</sup>. No entanto, a presen&#231;a de afec&#231;&#227;o reum&#225;tica n&#227;o justifica o aspecto morfol&#243;gico encontrado no septo interventricular dessa paciente<sup>6</sup>. Os achados cir&#250;rgico e ecocardiogr&#225;fico de intensa fibrose, afilamento e hipocinesia do septo interventricular n&#227;o s&#227;o observados na doen&#231;a reum&#225;tica, e essa hip&#243;tese tamb&#233;m n&#227;o explica a continuidade desse processo &#224; regi&#227;o da valva mitral<sup>6</sup>. Al&#233;m disso, a paciente n&#227;o apresentava hist&#243;ria pregressa de doen&#231;a reum&#225;tica. Seria de se esperar que os sinais e sintomas da doen&#231;a reum&#225;tica se manifestassem at&#233; a 4&#186; d&#233;cada de vida. Caracteristicamente, a doen&#231;a reum&#225;tica tem sua primeira manifesta&#231;&#227;o antes dos 20 anos de idade, e pode apresentar, posteriormente, como complica&#231;&#227;o a longo prazo, estenose mitral sintom&#225;tica, em m&#233;dia 20 anos ap&#243;s o comprometimento inicial da doen&#231;a<sup>7</sup>. No caso apresentado, a paciente n&#227;o possu&#237;a altera&#231;&#245;es da valva mitral, que indicassem poss&#237;vel acometimento por processo reum&#225;tico na ocasi&#227;o da miotomia/miectomia septal cir&#250;rgica, quando estava com 49 anos de idade. Se houvesse doen&#231;a reum&#225;tica, com essa idade, a paciente possivelmente j&#225; apresentaria comprometimento grave da valva, com a probabilidade de esse comprometimento ser diagnosticado em exames pr&#233;-operat&#243;rios e/ou de serem observadas altera&#231;&#245;es do aparelho valvar durante o procedimento cir&#250;rgico realizado na &#233;poca. Portanto, ao se observar, conjuntamente, as caracter&#237;sticas do caso apresentado, foi considerada m&#237;nima a probabilidade de a estenose mitral estar relacionada &#224; doen&#231;a reum&#225;tica.</p>
    <p>No que se refere &#224; possibilidade da presen&#231;a de processo degenerativo valvar no caso apresentado, a an&#225;lise anatomopatol&#243;gica &#233; bastante sugestiva. Os achados de grande calcifica&#231;&#227;o e espessamento do anel mitral s&#227;o caracter&#237;sticos do processo degenerativo<sup>6</sup>, o que j&#225; havia sido sugerido em 1985, por meio da ecocardiografia, e confirmado em 2003, com a retirada da valva mitral. A degenera&#231;&#227;o do anel da valva mitral pode, por si s&#243;, causar estenose mitral, principalmente em idosos, embora isso s&#243; seja observado em casos extremamente raros. Caracteristicamente, a insufici&#234;ncia mitral &#233; a ocorr&#234;ncia mais comum<sup>6</sup>. Al&#233;m disso, caracter&#237;sticas como espessamento da c&#250;spide com &#225;reas focais de calcifica&#231;&#227;o, espessamento e fus&#227;o de cordas tend&#237;neas, altera&#231;&#227;o morfol&#243;gica septal e, principalmente, &#225;reas de neovasculariza&#231;&#227;o n&#227;o est&#227;o presentes no processo degenerativo isolado. Embora, no nosso caso, a presen&#231;a de degenera&#231;&#227;o do anel valvar tenha continuado a ser considerada, n&#227;o foi feita associa&#231;&#227;o direta entre esse processo e a ocorr&#234;ncia de estenose mitral.</p>
    <p>Assim, partindo-se da observa&#231;&#227;o tanto cir&#250;rgica como ecocardiogr&#225;fica e anatomopatol&#243;gica, chegou-se &#224; conclus&#227;o de que a estenose mitral apresentada no caso presente resultou de uma extens&#227;o do processo cicatricial, que primariamente ocorreu no septo interventricular ap&#243;s a realiza&#231;&#227;o da miotomia/miectomia septal cir&#250;rgica, em 1985, e que, supostamente, por contig&#252;idade, acometeu tamb&#233;m a valva mitral. Essa extens&#227;o do processo cicatricial (caracteristicamente inflamat&#243;rio) justifica a presen&#231;a da intensa fibrose do septo interventricular n&#227;o restrita &#224; sua regi&#227;o basal, posteriormente alcan&#231;ando a c&#250;spide valvar.</p>
    <p>Este &#233;, portanto, o primeiro relato de caso em que a estenose mitral pode ser considerada uma poss&#237;vel forma de evolu&#231;&#227;o a longo prazo da miotomia/miectomia septal cir&#250;rgica. Poss&#237;veis causas ou fatores associados s&#227;o desconhecidos at&#233; o momento.</p>
    <p>
      <bold>Refer&#234;ncias</bold>
    </p>
    <p>1. Almeida DR, Diniz RVZ, Carvalho AS, Viegas RFM, Areosa CM, Carvalho AC et al. Incidence of the hypertrophic cardiomyopathy. Rev Soc Cardiol Estado de S&#227;o Paulo. 2000; 4: 431-4.</p>
    <p>2. De la Morena G, Ruiperez JA, Garcia Garcia J, Salas J, Jean E, Lopez Candel J. Hypertrophic myocardiopathy (I). The clinical and echocardiographic characteristics of a population of 72 patients. Rev Esp Cardiol 1991; 44: 11-7.</p>
    <p>3. Fighali S, Krajcer Z, Leachman RD. Septal myomectomy and mitral valve replacement for idiopathic subaortic stenosis: short and long-term follow-up. J Am Coll Cardiol 1984; 3: 1127-34.</p>
    <p>4. Wynne J, Braunwald E. Miocardiopatias e miocardites. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, et al. Harrison's Principles of Internal Medicine. 14 ed. Rio de Janeiro: McGraw-Hill Interamericana do Brasil; 1998. p.1417-23.</p>
    <p>5. Shapiro LM, Howat AP, Crean PA, Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J 1986; 7: 127-32.</p>
    <p>6. Schoen FJ. The heart. In: Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease. 6 ed. Rio de Janeiro: Guanabara Koogan; 2000 p. 486-539.</p>
    <p>7. Braunwald E. Valvopatias card&#237;acas. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD et al. Harrison's Principles of Internal Medicine. 14 ed. Rio de Janeiro: McGraw-Hill Interamericana do Brasil Ltda; 1998. p. 1400-13.</p>
    <p>8. Krajcer Z, Lufschanowski R, Angelini P, Leachman RD, Cookey DA. Septal myomectomy and mitral valve replacement for idiopathic hypertrophic subaortic stenosis. An echocardiographic and hemodynamic study. Circulation 1980; 62 (2 Pt 2) :I158-64.</p>
    <p>9. Pomerantzeff PMA, Brand&#227;o CMA, Stolf NAG, Oliveira SA. Surgical treatment of hypertrophic cardiomyopathy. Rev Soc Cardiol Estado de S&#227;o Paulo 2000; 4: 487-91.</p>
    <p>10. Gash AK, Ferri DP, Kolff J, Carabello BA, Spann JF. Coexisting mitral stenosis and dynamic left ventricular outflow obstruction. Cathet Cardiovasc Diagn 1983; 9: 381-90.</p>
    <p>
      <fn id="back10">
        <label>
          <bold>Endere&#231;o para correspond&#234;ncia</bold>
        </label>
        <p> R: Clemente Ferreira, 122/22 - Bairro Sto. Ant&#244;nio </p>
        <p> S&#227;o Caetano do Sul, SP - 09530-440 </p>
        <p> e-mail: </p>
        <p>
          <email xlink:href="alexandre.soeiro@bol.com.br">alexandre.soeiro@bol.com.br</email>
        </p>
      </fn>
    </p>
    <p>Recebido para publica&#231;&#227;o em 5/9/03 </p>
    <p>Aceito em 4/2/04</p>
  </body>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Severe mitral stenosis in the long-term evolution of myotomy-myectomy-septal resection</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>Severe mitral stenosis in the long-term evolution of myotomy-myectomy-septal resection</p>
      <p>Alexandre de Matos Soeiro; Juliana Ascen&#231;&#227;o de Souza; Carlos Vicente Serrano J&#250;nior; Luiz Alberto Benvenuti; Reynaldo Castro Miranda; Jos&#233; Carlos Nicolau; Jos&#233; Ant&#244;nio F. Ramires; S&#233;rgio Almeida de Oliveira</p>
      <p> S&#227;o Paulo, SP - Brazil</p>
      <p>InCor of the Hospital das Cl&#237;nicas of the FMUSP</p>
      <p>
        <xref ref-type="corresp" rid="back10-body2">Correspondence</xref>
      </p>
      <p>
        <italic>The patient is a 67-year-old female with severe nonrheumatic mitral stenosis occurring 18 years after myotomy-myectomy-septal resection for correction of asymmetric septal hypertrophic cardiomyopathy. The stenotic mitral valve was replaced by a mechanical prosthesis. The combination of 2 extremely rare syndromes with a poor prognosis made this patient a unique case.</italic>
      </p>
      <p>Hypertrophic cardiomyopathy, also known as idiopathic hypertrophic subaortic stenosis or hypertrophic obstructive cardiomyopathy, is a disease classically characterized by nondilated left ventricular hypertrophy in the absence of any other cause of increase in myocardial mass<sup>1-4</sup>. Its incidence in the general population ranges from 0.02% to 5% <sup>1,5</sup>. In approximately half of the cases, hypertrophic cardiomyopathy is a genetic disease, with a dominant autosomal transmission and variable expression; in the remaining cases, it may result from new mutations or recessive autosomal transmission with reduced penetrance of the gene<sup>1,4,6</sup>.</p>
      <p>The pattern of myocardial hypertrophy is usually heterogeneous, and contiguous segments of the left ventricle may greatly differ in their thickness. More frequently, the hypertrophy involves the interventricular septum, whose thickness is disproportionately increased in regard to the free left ventricular wall, characterizing asymmetric septal hypertrophic cardiomyopathy<sup>2,4-6</sup>. Independently of its morphological pattern, asymmetric septal hypertrophic cardiomyopathy has a bizarre and disorganized arrangement of the muscle cells in the septum, with alteration in the myofibrillar architecture, regardless of the presence or absence of an intraventricular systolic pressure gradient. In addition, variable myocardial fibrosis and thickening of the small intramural coronary arteries may be present. The pathophysiological abnormality present is diastolic, characterized by greater stiffness of the hypertrophied muscle, which primarily results from an abnormality in the management of intracellular calcium, causing an increase in diastolic filling pressures <sup>4, 6</sup>.</p>
      <p>Approximately 5% to 10% of the patients with asymmetric septal hypertrophic cardiomyopathy are refractory to clinical treatment and are indicated for more aggressive therapies, such as myotomy-myectomy-septal resection, dual-chamber pacemaker implantation, alcohol injection in the septal artery, defibrillator implantation (used in cases at high risk for sudden death), and even heart transplantation <sup>3,4</sup>.</p>
      <p>Mitral stenosis is usually of rheumatic origin, occurring mainly among women (approximately 66% of the cases), but in rare cases, it may be congenital <sup>7</sup>. Pure or predominant mitral stenosis occurs in approximately 40% of all patients with rheumatic heart disease <sup>7</sup>. The clinical findings are extremely varied and have a significant relation with the degree of valvular impairment. These findings may vary from the mere presence of some clinical signs without symptoms until the presence of pulmonary edema, atrial arrhythmias, hemoptysis, and right ventricular failure <sup>7</sup>.</p>
      <p>Until the present time, however, from the pathophysiological point of view, no cases of an association of myotomy-myectomy-septal resection and the appearance of long-term mitral stenosis have been reported in the scientific literature.</p>
      <p>We report the case of a 67-year-old female, who, 18 years after undergoing myotomy-myectomy-septal resection for correction of asymmetric septal hypertrophic cardiomyopathy, had symptoms of severe mitral stenosis. The patient presented to the Instituto do Cora&#231;&#227;o (InCor) of the Hospital das Cl&#237;nicas of the FMUSP for appropriate clinical assessment, being then referred for surgery.</p>
      <p>
        <bold>Case report</bold>
      </p>
      <p>We report the case of a 67-year-old female of mixed heritage, born in the city of Montes Claros, in the state of Minas Gerais, and coming from the city of Belo Horizonte, in the state of Minas Gerais, who complained of progressive dyspnea for 1 year, which was lately triggered by minimum exertion (New York Heart Association functional class III). The patient reported, as personal antecedents, systemic arterial hypertension and dyslipidemia, in addition to ischemic stroke in 1995, with no sequelae.</p>
      <p>In 1985, after undergoing complementary examinations, asymmetric septal hypertrophic cardiomyopathy and pulmonary hypertension were diagnosed. On that occasion, the patient had progressive dyspnea and dizziness but denied any history of rheumatic disease. Myotomy-myectomy-septal resection was indicated and performed through an aortotomy. The anatomicopathological study of the left ventricular fragments removed during the surgery showed hypertrophic cardiomyocytes and areas of disarrangement and fibrosis. In the postoperative period, the patient had atrial fibrillation and complete atrioventricular block, which required the implantation of a definitive pacemaker. Postoperative transthoracic echocardiography showed residual myocardial hypertrophy (interventricular septum thickness of 1.8 cm), preserved left ventricular function, and no signs of subaortic obstruction. Calcification of the mitral valve ring was also observed, but neither valvular insufficiency nor stenosis was identified.</p>
      <p>Both clinical and echocardiographic control during the following years showed a progressive enlargement of the left atrium, without worsening of the myocardial hypertrophy, but with evident mitral valvular impairment due to stenosis. In 2002, progressive dyspnea on exertion appeared, as well as nocturnal paroxysmal dyspnea, but with no other cardiovascular symptoms. The patient sought medical care on that occasion, when transthoracic echocardiography was performed (<xref ref-type="fig" rid="fig1-body2">fig. 1</xref>), revealing significant enlargement of the left atrium (5.7 cm of diameter), a mean mitral transvalvular gradient of 18 mmHg, and a peak gradient of 31 mmHg, with a reduction in the valvular area (1.15 cm&#178;). The diagnosis of moderate to severe mitral stenosis was established, and the existence of pulmonary hypertension (pulmonary artery systolic pressure of 64 mmHg) was evidenced. In addition, a relatively hyperechoic morphologically altered interventricular septum was observed, with thinning in its basal, middle, and apical portions, and asynchronous motion. The overall systolic function was preserved with an ejection fraction of 80%.</p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf01-en.jpg"/></fig>
      <p>Despite the medicamentous treatment with amiodarone (200 mg/day), furosemide (40 mg/day), phenytoin (100 mg/day), verapamil (120 mg/day), and warfarin (5 mg/day), the patient showed no clinical improvement. Thus, in April 2003, the patient was hospitalized, so that her clinical status could be better assessed through an adequate diagnostic investigation.</p>
      <p>On physical examination, the patient was in regular general condition, acyanotic, anicteric, hydrated, eupneic, and had healthy coloring. Her blood pressure was 130/70 mmHg. Jugular venous distension was observed at 45&#186;, crepitant rales were heard on both pulmonary bases, and the liver was tender and palpated 4 cm from the costal margin in the right midclavicular line. On cardiac auscultation, her heart rate was 70 bpm, her rhythm was regular, the intensity of the mitral (M1) and pulmonary (P2) components of the first and second cardiac sounds, respectively, was increased, and a diastolic murmur could be heard on the aortic and mitral positions. The electrocardiogram showed a baseline rhythm of atrial fibrillation, with a pacemaker functioning at a heart rate of 70 bpm. The chest X-ray in the posteroanterior and left lateral projections (<xref ref-type="fig" rid="en_21432f2-body2">fig. 2</xref>) showed signs suggestive of mitral stenosis and pulmonary hypertension. Transesophageal echocardiography (<xref ref-type="fig" rid="fig3-body2">fig. 3</xref>) showed significant stenosis of the mitral valve (area of 1cm&#178;), mild mitral insufficiency, and no intracavitary thrombi. Cinecoronary angiography and ventriculography showed the presence of normal coronary arteries, a calcified mitral valve, and preserved LV function.</p>
      <p content-type="asset">
        <fig id="en_21432f2-body2">
          <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf02-en.jpg"/></fig>
      </p>
      <fig id="fig3-body2">
        <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf03-en.jpg"/></fig>
      <p>Because of the clinical findings of severe mitral stenosis, surgical treatment for the mitral valve was chosen, with replacement of the stenotic valve by a St. Jude 25-mm mechanical prosthesis. On surgical field inspection, the mitral valve was intensely thickened and stenotic, with extensive calcification of its ring, which extended from the valve to the left ventricular apex. Still during surgery, a 2.3 x 2.0 x 0.8 cm fragment of the mitral valve was removed, and its anatomicopathological study showed thickening of the leaflet and chordae tendineae, with focal areas of calcification of the leaflet and fusion of the chordae tendineae (<xref ref-type="fig" rid="fig4-body2">fig. 4</xref>). On histological examination (<xref ref-type="fig" rid="fig5-body2">fig. 5</xref>), fibrosis, mucoid degeneration, calcification, and focal areas of neovascularization were observed. Calcification was also observed to occur mainly close to the insertion border of the leaflet (valvular ring).</p>
      <fig id="fig4-body2">
        <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf04-en.jpg"/></fig>
      <fig id="fig5-body2">
        <graphic xlink:href="1678-4170-abc-83-03-0253-00009-gf05-en.jpg"/></fig>
      <p>In the postoperative period, the patient had complications, such as a delay in extubation due to pulmonary congestion and the need for vasoactive and inotropic drugs (noradrenaline, dobutamine, and milrinone). The patient evolved with respiratory infection and acute renal failure, with complete reversion of the findings after adequate therapy was instituted.</p>
      <p>On postoperative echocardiography, the presence of a normofunctioning mechanical prosthesis was observed in the mitral position, with a valvular area of 2.7 cm&#178;. In addition, maintenance of pulmonary hypertension (pulmonary artery systolic pressure of 61 mmHg) and preserved left ventricular function were observed.</p>
      <p>The patient was discharged from the hospital after 46 days of hospitalization, in good general condition and with a significant improvement in functional class (New York Heart Association functional class I). On hospital discharge, the following drugs were prescribed: warfarin (5 mg/day); losartan (50 mg/day); amiodarone (200 mg/day); and hydrochlorothiazide (25 mg/day).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Asymmetric septal hypertrophic cardiomyopathy is usually greatly heterogeneous in its morphology, its clinical features, and its evolution <sup>1-4</sup>. In a considerable number of cases, asymmetric septal hypertrophic cardiomyopathy has been reported in association with valvular changes, mostly mitral insufficiency, which usually resolves after myotomy-myectomy-septal resection is performed <sup>2-5,8</sup>. More commonly, the mitral insufficiency occurring in asymmetric septal hypertrophic cardiomyopathy follows the obstruction caused by the systolic anterior motion of the mitral valve <sup>2-4, 8</sup>.</p>
      <p>A study by la Morena et al <sup>2</sup> assessed, by means of echocardiography, the characteristics of a population of 72 patients with hypertrophic cardiomyopathy, 31 of whom had asymmetric septal hypertrophic cardiomyopathy. Of their patients with hypertrophic cardiomyopathy, 44 had mitral insufficiency, which was mild in 25 patients, moderate in 15, and severe in 4. This shows the close relation between hypertrophic cardiomyopathy and that valvular problem <sup>2</sup>. In addition, in 33 patients with systolic anterior motion of the mitral valve, the occurrence of mitral insufficiency was 78.7%, while in those with no systolic anterior motion of the mitral valve, that index was 46.1% <sup>2</sup>.</p>
      <p>Currently, 5% to 10% of the patients are refractory to clinical treatment, and more aggressive therapies should be indicated in these patients. Myotomy-myectomy-septal resection continues to be an important alternative to the treatment of asymmetric septal hypertrophic cardiomyopathy, being, up to the present moment, the preferred choice in very symptomatic patients, who do not respond to clinical treatment, or in cases with a baseline pressure gradient <underline>&gt;</underline> 30 mmHg <sup>3,4,8,9</sup>. In many cases, myotomy-myectomy-septal resection is performed in association with reconstruction of the mitral ring <sup>3,8,9</sup>. However, replacement of the mitral valve should be the exception and performed only in cases of great hypertrophy with severe mitral insufficiency <sup>9</sup>.</p>
      <p>Fighali et al <sup>3</sup> studied 36 patients with hypertrophic cardiomyopathy undergoing surgical procedures, 6 of whom underwent myotomy-myectomy-septal resection, and 9 underwent that procedure in association with repair of the mitral valve. In the first group, 1 patient was not diagnosed with mitral insufficiency, 4 had mild mitral insufficiency, and 1 had moderate mitral insufficiency. In the second group, mitral insufficiency was mild in 3 patients, moderate in 2, and severe in 4. After surgery, a significant improvement in mitral insufficiency was observed in both groups, and only 1 patient remained with mild valvular insufficiency in each group <sup>3</sup>.</p>
      <p>Therefore, myotomy-myectomy-septal resection improves asymmetric septal hypertrophic cardiomyopathy in association with mitral insufficiency. In addition, the appearance of mitral insufficiency after myotomy-myectomy-septal resection is not frequent.</p>
      <p>Current survival for this type of surgery is around 80% in 10 years, with good immediate and late results in regard to symptom improvement. In the immediate postoperative period, approximately 70% of the cases already have expressive improvement in symptoms. In-hospital mortality, however, ranges from approximately 0% to 17.6%, depending mainly on the age group affected, and intraoperative mortality is close to 5%. The major complications of this procedure reported so far are as follows: complete atrioventricular block (incidence between 5% and 7%), interventricular septal defect, endocarditis, and thromboembolism <sup>3,4,8,9</sup>.</p>
      <p>Cases of mitral stenosis in association with hypertrophic cardiomyopathy or with myotomy-myectomy-septal resection are rare; when present, this association occurs in patients with previous rheumatic disease <sup>5,10</sup>. Therefore, no correlation exists between these 2 diseases. Up to the present time, no case has been reported in the scientific literature showing, from the pathophysiological point of view, a relation between asymmetric septal hypertrophic cardiomyopathy or myotomy-myectomy-septal resection and the appearance of mitral stenosis.</p>
      <p>We report the evolution of a female patient with asymmetric septal hypertrophic cardiomyopathy, with no previous history of rheumatic disease, who developed mitral stenosis after undergoing myotomy-myectomy-septal resection.</p>
      <p>In the anatomicopathological analysis of the valve performed in the leaflet fragment removed during the last surgery, we observed characteristics that could be present in degenerative and rheumatic processes, or in a possible extension of the healing process due to resection of the basal region of the interventricular septum performed during myotomy-myectomy-septal resection 18 years before.</p>
      <p>The gross and microscopic characteristics reported, especially those concerning neovascularization, could be found in the rheumatic process, due to its inflammatory character <sup>6,7</sup>. However, the presence of the rheumatic process does not justify the morphological aspect found in the interventricular septum of this patient <sup>6</sup>. The surgical and echocardiographic findings of intense fibrosis, thinning, and hypokinesia of the interventricular septum are not observed in rheumatic disease, and this hypothesis does not also explain the continuity of the process to the region of the mitral valve <sup>6</sup>. In addition, the patient did not have a previous history of rheumatic disease. It would be expected that the signs and symptoms of rheumatic disease would manifest until the fourth decade of life. Characteristically, rheumatic disease has its first manifestation before the age of 20 years, and, on average, 20 years later, symptomatic mitral stenosis may appear as a long-term complication <sup>7</sup>. In the present case, the patient had no alterations in the mitral valve that could indicate a possible impairment due to the rheumatic process on the occasion of myotomy-myectomy-septal resection at the age of 49 years. If rheumatic disease existed at that age, the patient might already have severe impairment of the valve, and this impairment might have been diagnosed on the preoperative examinations, or the alterations in the valvular apparatus might have been observed during the surgical procedure performed on the occasion. Therefore, when the characteristics of the present case are seen as a whole, the chance that mitral stenosis is related to rheumatic disease is considered minimal.</p>
      <p>In regard to the possibility of the presence of a valvular degenerative process in the present case, the anatomicopathological analysis is very suggestive. The findings of extensive calcification and thickening of the mitral valve are characteristic of a degenerative process <sup>6</sup>, which had already been suggested in 1985 on echocardiography, and confirmed in 2003, with removal of the mitral valve. Degeneration of the mitral valve ring could, by itself, cause mitral stenosis, mainly in the elderly, although this is seen only in extremely rare cases. Characteristically, mitral insufficiency is the most common occurrence <sup>6</sup>. Moreover, characteristics, such as thickening of the leaflet with focal areas of calcification, thickening, and fusion of the chordae tendineae, septal morphological alteration, and, mainly, areas of neovascularization, are not present in the isolated degenerative process. Although, in our case, the presence of degeneration of the valvular ring continued to be considered, the direct association of this process with the occurrence of mitral stenosis was not performed.</p>
      <p>Therefore, based on the surgical, echocardiographic, and anatomicopathological observations, the mitral stenosis of the present case was concluded to result from an extension of the healing process, which occurred primarily in the interventricular septum after the myotomy-myectomy-septal resection performed in 1985. This healing process is supposed to have also affected the contiguous mitral valve. This extension of the healing process (characteristically inflammatory) justifies the presence of the intense fibrosis in the interventricular septum not restricted to its basal region, later reaching the valvular leaflet.</p>
      <p>Therefore, this is the first report of a case in which mitral stenosis may be considered a possible form of long-term evolution of myotomy-myectomy-septal resection. Possible causes or associated factors are yet to be found.</p>
      <p>
        <bold>References</bold>
      </p>
      <p>1. Almeida DR, Diniz RVZ, Carvalho AS, et al. Incidence of the hypertrophic cardiomyopathy. Rev Soc Cardiol Est S&#227;o Paulo 2000; 4: 431-4.</p>
      <p>2. De la Morena G, Ruiperez JA, Garcia Garcia J, Salas J, Jean E, Lopez Candel J. Hypertrophic myocardiopathy (I). The clinical and echocardiographic characteristics of a population of 72 patients. Rev Esp Cardiol 1991; 44: 11-7.</p>
      <p>3. Fighali S, Krajcer Z, Leachman RD. Septal myomectomy and mitral valve replacement for idiopathic subaortic stenosis: short and long-term follow-up. J Am Coll Cardiol 1984; 3: 1127-34.</p>
      <p>4. Wynne J, Braunwald E. Miocardiopatias e miocardites. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, et al. Harrison's Principles of Internal Medicine. 14th ed. Rio de Janeiro: McGraw-Hill Interamericana do Brasil; 1998: c1417-23.</p>
      <p>5. Shapiro LM, Howat AP, Crean PA, Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J 1986; 7: 127-32.</p>
      <p>6. Schoen FJ. The heart. In: Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease. 6th ed. Rio de Janeiro: Guanabara Koogan; 2000: 486-539.</p>
      <p>7. Braunwald E. Valvopatias card&#237;acas. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, et al. Harrison's Principles of Internal Medicine. 14th ed. Rio de Janeiro: McGraw-Hill Interamericana do Brasil Ltda; 1998: 1400-13.</p>
      <p>8. Krajcer Z, Lufschanowski R, Angelini P, Leachman RD, Cookey DA. Septal myomectomy and mitral valve replacement for idiopathic hypertrophic subaortic stenosis. An echocardiographic and hemodynamic study. Circulation 1980; 62 (2 Pt 2): I158-64.</p>
      <p>9. Pomerantzeff PMA, Brand&#227;o CMA, Stolf NAG, Oliveira SA. Surgical treatment of hypertrophic cardiomyopathy. Rev Soc Cardiol Est S&#227;o Paulo 2000; 4: 487-91.</p>
      <p>10. Gash AK, Ferri DP, Kolff J, Carabello BA, Spann JF. Coexisting mitral stenosis and dynamic left ventricular outflow obstruction. Cathet Cardiovasc Diagn 1983; 9: 381-90.</p>
      <p>
        <fn id="back10-body2" fn-type="corresp">
          <label>
            <bold>Correspondence to</bold>
          </label>
          <p> Alexandre de Matos Soeiro </p>
          <p> Rua Clemente Ferreira, 122/22 </p>
          <p> 09530-440 - S&#227;o Caetano do Sul, SP, Brazil</p>
          <p> e-mail: </p>
          <p>
            <email xlink:href="alexandre.soeiro@bol.com.br">alexandre.soeiro@bol.com.br</email>
          </p>
        </fn>
      </p>
      <p>Received for publication: 9/5/03</p>
      <p>Accepted for publication: 2/4/04</p>
      <p>English version by Stela Maris Costalonga</p>
      <p>6. Schoen FJ. The heart. In: Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease. 6 ed. Rio de Janeiro: Guanabara Koogan; 2000 p. 486-539.</p>
    </body>
  </sub-article>
</article>
